On April 30, Gelonghui | Conoa-B (02162.HK) issued an announcement. The application for marketing licensing of drugs with spiquimab injections to treat seasonal allergic rhinitis has recently been accepted by the China Drug Administration (“State Drug Administration”). This report is based on a multi-center, randomized, double-blind, placebo-controlled phase III study, which is mainly used to confirm the efficacy and safety of spiquivizumab injections for patients with seasonal allergic rhinitis in adults with poor control of nasal glucocorticoids or other treatments. The study results showed that the phase III clinical trial data were positive, and the main endpoints were fully met. The spiqibizumab group was significantly superior to the placebo group, had highly significant statistical differences, and was safe.